Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer

Lung cancer is the leading cause of cancer-related deaths. Small cell lung cancer (SCLC) accounts for 15–25% of all lung cancers. It exhibits a rapid doubling time and a high degree of invasiveness. Additionally, overexpression of c-Kit occurs in 70% of SCLC patients. In this study, we evaluated an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kwang-Hyeok, Kim, Jin-Ock, Park, Jeong-Yang, Seo, Min-Duk, Park, Sang Gyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875948/
https://www.ncbi.nlm.nih.gov/pubmed/35216379
http://dx.doi.org/10.3390/ijms23042264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875948/
https://www.ncbi.nlm.nih.gov/pubmed/35216379
http://dx.doi.org/10.3390/ijms23042264

Ejemplares similares